Image

Breaking News

Featured image for “Jimmy Carter: A Life that Shaped Cancer Treatment and Hope for Melanoma Patients”
12/30/2024

Jimmy Carter: A Life that Shaped Cancer Treatment and Hope for Melanoma Patients

Former U.S. President Jimmy Carter, who passed away on December 29, 2024, at the age of 100, will be remembered…
Blog - Melanoma360
Breaking News
Featured image for “Bristol Myers Squibb Announces Approval for Subcutaneous Nivolumab”
12/27/2024

Bristol Myers Squibb Announces Approval for Subcutaneous Nivolumab

The Food and Drug Administration approval provides another option for cancer patients December 27, 2024 (Sacramento, California) The FDA has…
Blog - Melanoma360
Breaking News
Melanoma Research
Featured image for “Replimune Receives Breakthrough Therapy Designation for RP1 and Submits BLA to FDA”
11/22/2024

Replimune Receives Breakthrough Therapy Designation for RP1 and Submits BLA to FDA

Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval…
Blog - Melanoma360
Breaking News
Featured image for “Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma”
06/06/2024

Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma

Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in…
Blog - Melanoma360
Breaking News
Melanoma Research
Featured image for “The FDA Approval of TIL Therapy and What it Means for Advanced Melanoma”
03/15/2024

The FDA Approval of TIL Therapy and What it Means for Advanced Melanoma

An exciting new development in melanoma treatment is the recent FDA approval of Lifileucel (AMTAVGI) therapy, which harnesses the power…
Blog - Melanoma360
Breaking News
Melanoma Research
Featured image for “EXCLUSIVE WEBINAR: The FDA Approval of TIL Therapy and What it Means for Advanced Melanoma”
03/07/2024

EXCLUSIVE WEBINAR: The FDA Approval of TIL Therapy and What it Means for Advanced Melanoma

An exciting new development in melanoma treatment is the recent FDA-approval of Lifileucel (AMTAVGI) therapy, which harnesses the power of…
Blog - Melanoma360
Breaking News
Featured image for “Iovance Biotherapeutics Announces Approval for TIL Therapy”
02/17/2024

Iovance Biotherapeutics Announces Approval for TIL Therapy

The Food and Drug Administration approval provides another option for advanced, refractory melanoma February 16, 2024 (Richmond, California) The FDA…
Blog - Melanoma360
Breaking News
Melanoma Research
Featured image for “FDA Approves First AI-Powered Skin Cancer Diagnostic Tool”
01/18/2024

FDA Approves First AI-Powered Skin Cancer Diagnostic Tool

FDA Approves First AI-Powered Skin Cancer Diagnostic Tool The DermaSensor device demonstrates a high rate of sensitivity in the detection…
Blog - Melanoma360
Breaking News
Melanoma Research
Featured image for “Immunocore Presents Three-Year Overall Survival Data from the KIMMTRAK Phase 3 Trial”
10/23/2023

Immunocore Presents Three-Year Overall Survival Data from the KIMMTRAK Phase 3 Trial

Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trial Published: Oct 21, 2023 Data published in New…
Blog - Melanoma360
Breaking News
Melanoma Research
Featured image for “Opdivo® (nivolumab) Approved as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma”
10/15/2023

Opdivo® (nivolumab) Approved as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma

October 13, 2023 17:30 ET| Source: Bristol Myers Squibb In the Phase 3 CheckMate -76K trial, Opdivo demonstrated a statistically significant…
Blog - Melanoma360
Breaking News
Melanoma Research
12/30/2024

Jimmy Carter: A Life that Shaped Cancer Treatment and Hope for Melanoma Patients

Former U.S. President Jimmy Carter, who passed away on December 29, 2024, at the age of 100, will be remembered…
Featured image for “Jimmy Carter: A Life that Shaped Cancer Treatment and Hope for Melanoma Patients”
Blog - Melanoma360
 | 
Breaking News
12/27/2024

Bristol Myers Squibb Announces Approval for Subcutaneous Nivolumab

The Food and Drug Administration approval provides another option for cancer patients December 27, 2024 (Sacramento, California) The FDA has…
Featured image for “Bristol Myers Squibb Announces Approval for Subcutaneous Nivolumab”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
11/22/2024

Replimune Receives Breakthrough Therapy Designation for RP1 and Submits BLA to FDA

Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval…
Featured image for “Replimune Receives Breakthrough Therapy Designation for RP1 and Submits BLA to FDA”
Blog - Melanoma360
 | 
Breaking News
06/06/2024

Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma

Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in…
Featured image for “Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
03/15/2024

The FDA Approval of TIL Therapy and What it Means for Advanced Melanoma

An exciting new development in melanoma treatment is the recent FDA approval of Lifileucel (AMTAVGI) therapy, which harnesses the power…
Featured image for “The FDA Approval of TIL Therapy and What it Means for Advanced Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
03/07/2024

EXCLUSIVE WEBINAR: The FDA Approval of TIL Therapy and What it Means for Advanced Melanoma

An exciting new development in melanoma treatment is the recent FDA-approval of Lifileucel (AMTAVGI) therapy, which harnesses the power of…
Featured image for “EXCLUSIVE WEBINAR: The FDA Approval of TIL Therapy and What it Means for Advanced Melanoma”
Blog - Melanoma360
 | 
Breaking News
02/17/2024

Iovance Biotherapeutics Announces Approval for TIL Therapy

The Food and Drug Administration approval provides another option for advanced, refractory melanoma February 16, 2024 (Richmond, California) The FDA…
Featured image for “Iovance Biotherapeutics Announces Approval for TIL Therapy”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
01/18/2024

FDA Approves First AI-Powered Skin Cancer Diagnostic Tool

FDA Approves First AI-Powered Skin Cancer Diagnostic Tool The DermaSensor device demonstrates a high rate of sensitivity in the detection…
Featured image for “FDA Approves First AI-Powered Skin Cancer Diagnostic Tool”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
10/23/2023

Immunocore Presents Three-Year Overall Survival Data from the KIMMTRAK Phase 3 Trial

Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trial Published: Oct 21, 2023 Data published in New…
Featured image for “Immunocore Presents Three-Year Overall Survival Data from the KIMMTRAK Phase 3 Trial”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
10/15/2023

Opdivo® (nivolumab) Approved as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma

October 13, 2023 17:30 ET| Source: Bristol Myers Squibb In the Phase 3 CheckMate -76K trial, Opdivo demonstrated a statistically significant…
Featured image for “Opdivo® (nivolumab) Approved as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research